Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tejinder Glamour

Gastroenterology Pinellas Park, FL Medical Doctor

NPI 1043282569 CMS profile 183112

6225 66Th St N, Pinellas Park, FL 33781

Open in the dashboard

General payments

$13,834

624 records reported · program years 2019–2025

Research payments

$2,224

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$202,292 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Tejinder Glamour of Pinellas Park, FL is reported in the CMS Open Payments database as having received $13,834 across 624 general payments and $2,224 in research payments paid to them. Separately, studies naming them as principal investigator received $202,292 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,044 87
2024 General $1,869 84
2023 General $2,232 117
2022 General $1,324 72
2021 General $3,583 97
2020 General $1,024 63
2020 Research $805 2
2019 General $1,758 104
2019 Research $1,419 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tejinder Glamour
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Tejinder Glamour were reported at $2,044. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Tejinder Glamour Gastroenterology median Middle half National median
2019 $1,758 $417 $126–$1,100 $163
2020 $1,024 $224 $74–$624 $114
2021 $3,583 $352 $106–$1,054 $132
2022 $1,324 $448 $129–$1,270 $149
2023 $2,232 $533 $150–$1,390 $160
2024 $1,869 $605 $160–$1,606 $164
2025 $2,044 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $2,773 54 payments
  2. AbbVie, Inc. $2,700 168 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $985 55 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $879 55 payments
  5. Janssen Biotech, Inc. $632 23 payments
  6. Pfizer Inc. $587 33 payments
  7. Braintree Laboratories, Inc. $536 19 payments
  8. QOL Medical, LLC $514 21 payments
  9. Ardelyx, Inc. $345 14 payments
  10. VIVUS, Inc. $335 18 payments
  11. Other $3,546 164 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,236 609 payments
  2. Consulting Fee $2,060 1 payment
  3. Gift $401 11 payments
  4. Education $137 3 payments
Products named General payments · program years 2019–2025
  1. Vemlidy $2,060 1 payment
  2. CREON $1,389 95 payments
  3. LINZESS $933 63 payments
  4. XIFAXAN $669 41 payments
  5. ENTYVIO $590 30 payments
  6. XELJANZ $573 32 payments
  7. STELARA $516 19 payments
  8. RINVOQ $512 27 payments
  9. Sucraid $435 18 payments
  10. SUPREP BOWEL PREP $423 13 payments
  11. Other $7,808 377 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,224 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,801

Median for Gastroenterology: 569

Drug cost

$1,557,301

Median for Gastroenterology: $104,976

Branded share of claims

45.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 15 $398,676
Epclusa Sofosbuvir/Velpatasvir Brand 12 $289,248
Creon Lipase/Protease/Amylase Brand 34 $227,655
Xifaxan Rifaximin Brand 55 $173,687
Linzess Linaclotide Brand 123 $127,631
Humira(Cf) Pen Adalimumab Brand 16 $113,462
Xeljanz Tofacitinib Citrate Brand 12 $65,187
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 181 $29,569
Trulance Plecanatide Brand 27 $24,603
Movantik Naloxegol Oxalate Brand 19 $17,594

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$108,216

Medicare's payments for the services billed

Medicare patients

477

Average age 73

Services billed

1,113

291 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 48%
Ischemic heart disease 27%
Depression 27%
Chronic kidney disease 26%
Diabetes 23%
COPD 21%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
$221 — —
RINVOQ
$130 — —
SKYRIZI
$130 — —
DUPIXENT
$129 — —
XIFAXAN
$112 55 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

628 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record